Dr. Zukerberg has expertise in gastrointestinal, hematological, and frozen section pathology.
- Centers & Specialties
- Clinical Interests
- Gastrointestinal cancer
- Liver cancer
- Pancreatic cancer
- Medical Education
- MD, UMDNJ Rutgers Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital|Fellowship, University of Michigan Hospitals
- Board Certifications
- Anatomic Pathology & Clinical Pathology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Dr. Zukerberg has expertise in gastrointestinal, hematological, and frozen section pathology. He is the Principal Investigator with a research program focused on studying the biology and biochemistry of a novel gene, Cables that interacts with cell cycle control proteins including, CDK2, p53, beta-catenin, mTOR and is a novel cell cycle regulator and tumor suppressor gene. Cables expression is lost in many primary human cancer and it loss can prolong the life of stem cells in some mouse organs. Some of the research projects of Dr. Zukerberg include studying the relationship of Cables to cell cycle control proteins, generating and studying Cables mutant mice, and determining the pathways involved in Cables cell growth regulation. Other recent projects have included identification of cyclin D1 as a marker of mantle cell lymphoma and understanding specific reactive conditions that mimic lymphoma.
- Research Summary
We have recently cloned a novel protein, Cables, which maps to human chromosome 18q and inhibits growth of cells in culture and tumor formation in animal models. Our studies will define a novel target for the deletions commonly seen on chromosome 18q. Ultimately, these studies will lay the foundation for new therapeutic approaches. See details at the Zukerberg Lab. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Zukerberg's profile at the Harvard Clinical and Translational Science Center.
- Age and Obesity Promote Methylation and Suppression of 5-Alpha Reductase 2- Implications for Personalized Therapy in Benign Prostatic Hyperplasia. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. J Urol. 2015 Apr 24. pii: S0022-5347(15)03861-6. doi: 10.1016/j.juro.2015.04.079. [Epub ahead of print]
- Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma. Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong W, Olumi A, Young RH, Wu CL.Hum Pathol. 2015 Mar 11. pii: S0046-8177(15)00079-9. doi: 10.1016/j.humpath.2015.02.013. [Epub ahead of print]
- Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer.Liang YX, Mo RJ, He HC, Chen JH, Zou J, Han ZD, Lu JM, Cai C, Zeng YR, Zhong WD, Wu CL. Oncol Rep. 2015 May;33(5):2648-54. doi: 10.3892/or.2015.3870. Epub 2015 Mar 20.
55 Fruit Street
Boston MA, 02114-2696